Amrize (NYSE:AMRZ) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Amrize (NYSE:AMRZ) had its price target hoisted by equities research analysts at JPMorgan Chase & Co. from $60.00 to $70.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 13.64% from the stock’s current price.

A number of other brokerages have also weighed in on AMRZ. Berenberg Bank set a $70.00 price objective on Amrize in a research report on Thursday, February 19th. Citigroup raised their price target on Amrize from $63.00 to $67.00 and gave the company a “buy” rating in a report on Thursday, January 8th. UBS Group lifted their price objective on Amrize from $53.00 to $57.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Royal Bank Of Canada increased their target price on Amrize from $60.00 to $61.00 and gave the company a “sector perform” rating in a research report on Thursday, February 19th. Finally, Oppenheimer reissued an “outperform” rating and issued a $70.00 target price (up from $64.00) on shares of Amrize in a report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $64.14.

Amrize Price Performance

Shares of AMRZ stock traded down $1.13 during mid-day trading on Thursday, hitting $61.60. The company had a trading volume of 4,375,599 shares, compared to its average volume of 3,527,711. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.64 and a quick ratio of 1.10. The stock’s 50 day moving average price is $57.47 and its 200-day moving average price is $53.31. Amrize has a 52-week low of $44.12 and a 52-week high of $65.94. The company has a market capitalization of $34.07 billion and a P/E ratio of 25.04.

Amrize (NYSE:AMRZ) last posted its earnings results on Tuesday, February 17th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.03. The company had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.95 billion. The firm’s revenue for the quarter was down .4% compared to the same quarter last year.

Insider Activity at Amrize

In other Amrize news, CFO Ian A. Johnston purchased 1,200 shares of Amrize stock in a transaction dated Thursday, February 19th. The shares were purchased at an average cost of $63.92 per share, for a total transaction of $76,704.00. Following the completion of the acquisition, the chief financial officer owned 18,544 shares in the company, valued at $1,185,332.48. This represents a 6.92% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Hedge Funds Weigh In On Amrize

Hedge funds have recently added to or reduced their stakes in the stock. MCF Advisors LLC purchased a new stake in shares of Amrize in the fourth quarter valued at approximately $27,000. Basepoint Wealth LLC bought a new stake in Amrize during the 4th quarter valued at $33,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Amrize in the 4th quarter worth $34,000. State of Wyoming purchased a new stake in shares of Amrize in the 3rd quarter worth $32,000. Finally, Itau Unibanco Holding S.A. grew its position in shares of Amrize by 150.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 750 shares of the company’s stock worth $41,000 after buying an additional 450 shares in the last quarter.

About Amrize

Amrize AG focuses on building materials business in North America. The company was incorporated in 2023 and is based in Zug, Switzerland. Amrize AG operates independently of Holcim AG as of June 23, 2025.